← Leaderboards
Neil J. Freedman
Duke University
$13,528,793
Attributed
$17,846,912
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,846,912 · 10
By mechanism
R01$14,908,871 · 8
T32$2,591,698 · 1
R21$346,343 · 1
Top collaborators
- Sudha K Shenoy9 shared
- Christopher Lee Holley4 shared
- Jonathan A Stiber4 shared
Most similar at Duke University
Same institution · by research overlap
- Walter J Koch$36,219,689
- Christopher Lee Holley$5,101,144
- Jonathan A Stiber$4,710,913
- Sudha K Shenoy$7,623,703
- Robert J Lefkowitz$17,365,480
Others in their field
Top investigators on “Congenic”
- Laurence Morel · University Of Texas Hlth Science Center$17,397,620
- Muriel T Davisson · Jackson Laboratory$14,544,634
- Shu Man Fu · University Of Virginia Charlottesville$14,307,646
- Bina Joe · University Of Toledo Health Sci Campus$13,846,251
- Clifford J Rosen · Icahn School Of Medicine At Mount Sinai$13,800,079
- Larry W Robertson · University Of Kentucky$11,188,191
Research focus
CongenicSignal TransductionAtherosclerosisMediatingIn VitroAtherogenesisProteinsInflammatorySmooth Muscle MyocytesCell ProliferationMolecularAntiatherogenicIn VivoResponseCytokineWestern DietCellsMacrophageApolipoprotein ETnf GeneNew Therapeutic TargetAffectVascular Smooth MuscleGenes
Grant awards (41)
Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis$586,990
R01 · FY2025 · HL · contact PI
Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis$575,250
R01 · FY2024 · HL · contact PI
Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis$586,990
R01 · FY2023 · HL · contact PI
Anti-Atherogenic Mechanisms of Drebrin$523,250
R01 · FY2023 · HL
Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis$586,990
R01 · FY2022 · HL · contact PI
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20$534,626
R01 · FY2022 · HL
Anti-Atherogenic Mechanisms of Drebrin$523,250
R01 · FY2022 · HL
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20$534,626
R01 · FY2021 · HL
Anti-Atherogenic Mechanisms of Drebrin$523,250
R01 · FY2021 · HL
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20$534,626
R01 · FY2020 · HL
Anti-Atherogenic Mechanisms of Drebrin$523,250
R01 · FY2020 · HL
Multidisciplinary Heart and Vascular Diseases$397,155
T32 · FY2020 · HL · contact PI
Multidisciplinary Heart and Vascular Diseases$631,332
T32 · FY2019 · HL · contact PI
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20$533,519
R01 · FY2019 · HL
Multidisciplinary Heart and Vascular Diseases$399,935
T32 · FY2018 · HL · contact PI
Multidisciplinary Heart and Vascular Diseases$582,884
T32 · FY2017 · HL · contact PI
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20$527,209
R01 · FY2017 · HL
Anti-atherogenic Mechanisms of the Dual Rho-GEF Kalirin$473,143
R01 · FY2017 · HL · contact PI
Multidisciplinary Heart and Vascular Diseases$4,805
T32 · FY2017 · HL · contact PI
Multidisciplinary Heart and Vascular Diseases$575,587
T32 · FY2016 · HL · contact PI
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20$555,034
R01 · FY2016 · HL
Anti-atherogenic Mechanisms of the Dual Rho-GEF Kalirin$473,143
R01 · FY2016 · HL · contact PI
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20$468,283
R01 · FY2015 · HL
Anti-atherogenic Mechanisms of the Dual Rho-GEF Kalirin$466,046
R01 · FY2015 · HL · contact PI
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20$44,520
R01 · FY2015 · HL
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20$474,576
R01 · FY2014 · HL
Anti-atherogenic Mechanisms of the Dual Rho-GEF Kalirin$467,191
R01 · FY2014 · HL · contact PI
Desensitization of Vascular Receptor Tyrosine Kinases$369,790
R01 · FY2009 · HL · contact PI
Desensitization of Vascular Receptor Tyrosine Kinases$369,790
R01 · FY2008 · HL · contact PI
Mechanisms of Arterial Wall-Mediated Atherogenesis$369,790
R01 · FY2008 · HL · contact PI
Mechanisms of Arterial Wall-Mediated Atherogenesis$369,790
R01 · FY2007 · HL · contact PI
Desensitization of Vascular Receptor Tyrosine Kinases$369,790
R01 · FY2007 · HL · contact PI
Aging, Atherosclerosis, and the Arterial Wall$155,180
R21 · FY2007 · AG · contact PI
Desensitization of Vascular Receptor Tyrosine Kinases$379,716
R01 · FY2006 · HL · contact PI
Mechanisms of Arterial Wall-Mediated Atherogenesis$379,614
R01 · FY2006 · HL · contact PI
Aging, Atherosclerosis, and the Arterial Wall$191,163
R21 · FY2006 · AG · contact PI
Desensitization of Vascular Receptor Tyrosine Kinases$387,605
R01 · FY2005 · HL
Mechanisms of Arterial Wall-Mediated Atherogenesis$387,500
R01 · FY2005 · HL
RECEPTOR KINASE GENE THERAPY FOR NEOINTIMAL HYPERPLASIA$340,137
R01 · FY2002 · HL
RECEPTOR KINASE GENE THERAPY FOR NEOINTIMAL HYPERPLASIA$330,228
R01 · FY2001 · HL
RECEPTOR KINASE GENE THERAPY FOR NEOINTIMAL HYPERPLASIA$339,359
R01 · FY2000 · HL